Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?

被引：6
|
作者：
Munir, Kashif M. [1 ]
Davis, Stephen N. [2 ]
机构：
[1] Univ Maryland, Sch Med, Ctr Diabet & Endocrinol, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, 22 South Greene St, Baltimore, MD 21201 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2018年 / 19卷 / 08期
关键词：
GLP-1 receptor agonist; SGLT2; inhibitor; type; 2; diabetes; cardiovascular outcomes; GLUCOSE-LOWERING DRUGS; CARDIOVASCULAR OUTCOMES; CVD-REAL; MORTALITY; EMPAGLIFLOZIN; LIRAGLUTIDE;
D O I：
10.1080/14656566.2018.1475559
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：773 / 777
页数：5
相关论文
共 50 条
  • [31] Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
    Brown, Emily
    Wilding, John P. H.
    Barber, Thomas M.
    Alam, Uazman
    Cuthbertson, Daniel J.
    OBESITY REVIEWS, 2019, 20 (06) : 816 - 828
  • [32] Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
    Wright, Alison K. K.
    Carr, Matthew J. J.
    Kontopantelis, Evangelos
    Leelarathna, Lalantha
    Thabit, Hood
    Emsley, Richard
    Buchan, Iain
    Mamas, Mamas A. A.
    van Staa, Tjeerd P. P.
    Sattar, Naveed
    Ashcroft, Darren M. M.
    Rutter, Martin K. K.
    DIABETES CARE, 2022, 45 (04) : 909 - 918
  • [33] Treatment discontinuation among users of SGLT2 inhibitors and GLP-1 receptor agonists in a national population of patients with type 2 diabetes
    Lim, C. -E.
    Pasternak, B.
    Eliasson, B.
    Ueda, P.
    DIABETOLOGIA, 2024, 67 : S205 - S205
  • [34] The Combined Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Cardiovascular Events among Patients with Type 2 Diabetes
    Azoulay, Laurent
    Simms-Williams, Nikita
    Yin, Hui
    Lu, Sally
    Treves, Nir
    Yu, Oriana Hoi Yun
    DIABETES, 2023, 72
  • [35] GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis
    Banerjee, Mainak
    Pal, Rimesh
    Maisnam, Indira
    Mukhopadhyay, Satinath
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2024, 18 (01)
  • [36] GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis
    Karagiannis, Thomas
    Tsapas, Apostolos
    Athanasiadou, Eleni
    Avgerinos, Ioannis
    Liakos, Aris
    Matthews, David R.
    Bekiari, Eleni
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 174
  • [37] Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Singh, Awadhesh Kumar
    Singh, Ritu
    WORLD JOURNAL OF CARDIOLOGY, 2022, 14 (06): : 329 - 342
  • [38] SGLT-2 inhibitors as second-line therapy in type 2 diabetes
    Tahrani, Abd A.
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (09): : 678 - 679
  • [39] Effectiveness of add-on therapy with SGLT2 inhibitors or GLP-1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study
    Baechle, Christina
    Rosenbauer, Joachim
    Stahl-Pehe, Anna
    Seufert, Jochen
    Mader, Julia K.
    Wagner, Christian
    Wosch, Frank-Juergen
    Erath, Dieter
    Holl, Reinhard W.
    Lanzinger, Stefanie
    DPV Sci Initiative
    German Ctr Diabetes Res DZD
    DIABETES OBESITY & METABOLISM, 2025, 27 (03): : 1591 - 1596
  • [40] Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond
    Olanrewaju, Olusegun A.
    Sheeba, Fnu
    Kumar, Avinash
    Ahmad, Saad
    Blank, Narendar
    Kumari, Reema
    Kumari, Komal
    Salame, Tamara
    Khalid, Ayesha
    Yousef, Nazdar
    Varrassi, Giustino
    Khatri, Mahima
    Kumar, Satish
    Mohamad, Tamam
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
12345